Nifluril Enfants (Morniflumate)

Morniflumate works by non‑selectively inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2. This inhibition lowers the production of prostaglandins, which are mediators of pain, fever, and inflammation, thereby producing analgesic and anti‑inflammatory effects at the site of injury.

The appropriate dose of Nifluril Enfants is determined by the prescribing healthcare professional based on the patient’s age, weight, clinical condition, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety of Morniflumate in pregnancy and lactation has not been firmly established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Morniflumate belongs to the fenamate subclass of NSAIDs, which differs chemically from more common propionic or acetic acid NSAIDs. It offers a rectal route that can be advantageous when oral administration is problematic, but its safety profile and drug‑interaction potential are similar to other non‑selective NSAIDs.

Store Nifluril Enfants at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the rectal dosage form is not damaged before use.

Nifluril Enfants is administered rectally. The prescribed dose is inserted into the rectum according to the instructions provided by the healthcare professional, usually using a suitable applicator or as directed on the product label.

Serious risks include gastrointestinal ulceration or bleeding, liver injury (hepatotoxicity), renal impairment, and severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of abdominal pain, dark stools, jaundice, reduced urine output, or rash, and seek medical attention promptly if they occur.

Nifluril Enfants should be avoided in patients with known hypersensitivity to Morniflumate or other fenamate NSAIDs, active gastrointestinal ulceration, severe renal or hepatic impairment, and in those where NSAID use is contraindicated, such as certain cardiovascular conditions without medical guidance.